Upadacitinib Monotherapy Hampers Joint Damage in RA: Study

Results:

In patients naïve or with limited exposure to methotrexate (SELECT-EARLY), mean changes from baseline to week 48 in mTSS were 0.03 for upadacitinib 15 mg, 0.14 for upadacitinib 30 mg, and 1.00 for methotrexate based on linear extrapolation (p < 0.001 for both upadacitinib doses vs methotrexate). Among patients with an inadequate response to methotrexate (SELECT-COMPARE), the mean change from baseline in mTSS was significantly reduced in the upadacitinib 15 mg plus methotrexate group vs placebo plus methotrexate (0.28 vs 1.73; p < 0.001); mean change from baseline in the adalimumab plus methotrexate group was 0.39.

Upadacitinib monotherapy or in combination with background methotrexate was effective in inhibiting the progression of structural joint damage through week 48 in methotrexate-naïve and methotrexate-IR patients with RA.

Reference:

Peterfy CG, Strand V, Friedman A, et al. Inhibition of Structural Joint Damage Progression with Upadacitinib in Rheumatoid Arthritis: 1-Year Outcomes from the SELECT Phase 3 Program [published online ahead of print, 2021 Dec 13]. Rheumatology (Oxford). 2021;keab861. doi:10.1093/rheumatology/keab861